HERAX Ventures invests in MagCath
HERAX Ventures is proud to announce our participation in the latest financing round for MagCath ApS.
The investment round will enable MagCath to further develop its female stress incontinence non-surgical medical device for instant bladder control. Three groups of users have tested Obtinu in clinical trials at the Copenhagen University Hospital. The doctors conclude, that Obtinu is safe and immediately efficient. In 2019 a new long-term trial will start to establish further evidence. The device replaces mesh surgery.
Please find more information on www.magcath.com
About HERAX Ventures
The purpose of HERAX Ventures is to support start-ups offering clinical or IT solutions to- or within the Pharmaceutical, Diagnostics, Consumer Health and Medical device area.
Both software, devices, concepts or new ideas at any level able to benefit from the support the HERAX Ventures organization can contact us for help.